Psychedelics and Schizophrenia: What the Research Says About Risk
Are Psychedelics a Treatment for Schizophrenia?
No. Psychedelic-assisted therapy is not an established or approved treatment for schizophrenia-spectrum disorders. Most modern psychedelic studies exclude people with psychosis or a high risk of psychosis because of concern that these drugs could worsen symptoms or trigger an episode in people who are vulnerable (1) (2).
Schizophrenia is a serious mental illness that can affect how a person thinks, feels, and relates to reality. It needs careful assessment and ongoing care. A discussion of research possibilities should never be confused with advice to use a psychedelic. At present, the safety questions are larger than the possible benefits.
Why Are People With Psychosis Risk Excluded From Trials?
Researchers exclude people with psychosis risk to avoid harm and to learn about a drug in a safer first group. A 2026 review stated that psychedelics can worsen existing psychotic illness and may trigger psychosis in vulnerable people. It also noted that the size of the risk is still hard to measure (1).
Clinical trial exclusion does not mean that every person will have the same response. It means researchers do not have enough evidence to call the drugs safe in this group. Trials often also exclude people with certain family histories, but screening rules vary. A personal clinician can help explain risk in the full context of someone’s health history.
What Does the Evidence Say About Psychosis Risk?
The evidence is limited and complex. A 2025 review and meta-analysis found very low rates of prolonged psychosis in modern clinical studies, but those studies usually excluded people with schizophrenia-spectrum disorders. The authors stressed that the schizophrenia evidence came from only a small number of older studies (2).
A large Ontario cohort study found an association between emergency visits involving hallucinogen use and later schizophrenia-spectrum diagnoses (3). That result does not prove that a hallucinogen caused the diagnosis. It examined people who had needed emergency care, not all people who use hallucinogens. It does show why severe reactions deserve serious attention.
Does an Association Prove Cause?
No. An association shows that two events occurred together more often than expected. It cannot explain why. Some people who need emergency care may already have unrecognized vulnerability, use other substances, or face severe stress. Observational studies cannot fully separate those factors from the role of the drug (3).
This distinction matters. It would be wrong to say that every hallucinogen use leads to schizophrenia. It would also be wrong to say that risk is not real because a study cannot prove cause. The safest conclusion is that people with psychosis risk need specialized care, not self-experimentation.
Are Researchers Still Discussing Future Studies?
Some researchers are discussing whether tightly controlled future studies could explore specific symptoms, such as negative or cognitive symptoms. These papers are frameworks, not clinical trials. Their authors identify the possible induction or worsening of psychosis as the main concern and call for unusually careful safety measures (4).
A research question is not a treatment recommendation. A person should not treat a theoretical paper as permission to test a drug. Future studies, if they occur, would need clinical oversight, clear stopping rules, and strong patient protections. None of that is available in unsupervised settings.
What Care Is Recommended for Schizophrenia?
Established care should come first. The National Institute of Mental Health describes coordinated specialty care as an evidence-based approach for early psychosis. It brings together medical care, therapy, family education, and shared decision-making. Treatment often includes medication, psychotherapy, and practical support for work, school, and relationships (5).
If a person has new hallucinations, intense paranoia, severe confusion, or cannot care for themselves, seek urgent help. In the United States, call or text 988 for mental-health crisis support. Call 911 or go to an emergency department if there is immediate danger. Do not wait for a substance-related problem to resolve on its own.
Where Can Someone Find Support After a Difficult Experience?
A difficult experience can leave a person scared, ashamed, or unsure what is real. Support should be grounded and safety-focused. Integration therapy may help a person process a past experience, but it does not replace psychiatric assessment, crisis care, medication management, or coordinated specialty care for psychosis.
Serenity’s article on when therapy falls short after a difficult psychedelic experience explains why extra support may be needed. For nonurgent processing after a past experience, integrative post-psychedelic support may offer a therapeutic space. For psychosis symptoms, start with qualified psychiatric or emergency care.
Disclaimer: The information in this article, including discussions of psychedelic-assisted psychotherapy, is for informational purposes only. Psychedelic-assisted psychotherapy has not been approved by all established. This content is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
References
(4) Wolf, G., et al. (2023). Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation. Molecular Psychiatry, 28, 44–58.(5) National Institute of Mental Health. (n.d.). Schizophrenia.
About the Author
About the Author: This article was written by Jeff Jones, a Licensed Professional Counselor (LPC) in Texas in practice since 1999. He is a 2024 graduate of the CIIS Center for Psychedelic Therapies and Research program. With a compassionate and evidence-based approach, he helps clients navigate life's challenges and find a path toward healing.